What Comes Next, and What You Can Do

10.1: The Pipeline Is Coming to Humans

The pipeline Conyngham used for Rosie is not an academic exercise or a stunt. It is the same approach now in human clinical trials at major pharmaceutical companies. BioNTech's autogene cevumeran is in trials for pancreatic cancer. Moderna's mRNA-4157, combined with Keytruda, is being tested in melanoma and expanding to colorectal and lung cancers. Multiple academic medical centers are running neoantigen vaccine trials. The steps are identical: sequence the tumor, call variants, predict neoantigens, design the mRNA, synthesize, administer. The technology Conyngham used in 2025 for a dog is what will be in oncology clinics for humans within the next few years.

What makes this moment distinct is the convergence of three independent technological revolutions. First, genome sequencing has become cheap enough to be routine, at two hundred dollars and dropping. Second, AI and AlphaFold have made protein structure prediction and biological reasoning accessible to non-specialists. Third, mRNA technology, stress-tested at pandemic scale, has proven itself as a platform that can produce personalized treatments at speed. Each revolution would be significant alone. Together, they represent a shift from standardized treatments for average patients to personalized treatments for individual tumors.

10.2: Understanding This Matters

You do not need to become a biologist to benefit from this revolution, but you need to become biologically literate. Within the next decade, genomic profiling will likely become routine medical care. Your doctor may recommend sequencing your tumor. Pharmaceutical companies may offer personalized vaccine options alongside standard chemotherapy. Understanding the basics (what sequencing reveals, what neoantigens are, how mRNA vaccines work, what AlphaFold does) will help you have informed conversations with healthcare providers, evaluate treatment options, and participate in decisions about your own care. This is health literacy for the twenty-first century.

If you want to go deeper, the resources have never been more accessible. Khan Academy offers free, high-quality lessons on genetics, molecular biology, and immunology. learngenomics.dev provides a programmer-friendly introduction to genomics. Rosalind.info offers interactive bioinformatics problems that teach you to work with real genomic data. The AlphaFold Server is free and requires no programming knowledge. The genetics-for-programmers roadmap on GitHub curates a learning path for people with a technical background. The barrier to entry has never been lower.

10.3: Closing

With great power comes the need for great care, and the tools in this book carry risks proportional to their potential. CRISPR can cure sickle cell disease, but it can also be used to edit embryos in ways whose consequences we cannot predict. AI can accelerate vaccine design, but it can also be directed at designing biological agents that should never exist. The He Jiankui case was a warning: the technology outpaced the ethical frameworks. As these tools become more powerful and more accessible, robust oversight, international coordination, and informed public engagement grow more urgent. Understanding the science is a prerequisite for participating in decisions about how these technologies are used.

And so we return to Rosie. By mid-March 2026, her largest tumor had shrunk by seventy-five percent. She had gained weight. She was chasing rabbits in the yard, an activity that, in the estimation of her owner, constitutes the highest quality of life a dog can achieve. One tumor remained non-responsive, and a second vaccine was in preparation. She was not cured; Conyngham has been the first to say so. But she was alive, energetic, and comfortable, months past the point when her veterinarians said there was nothing more they could do.

A man with no biology degree, armed with curiosity, computational skills, and AI tools that did not exist three years earlier, refused to accept that verdict. He connected with world-class scientists willing to collaborate across disciplinary boundaries. Together, they designed, manufactured, and administered a personalized mRNA cancer vaccine using a pipeline built almost entirely on open-source, freely available technology. It cost three thousand dollars for the sequencing and a few months of intense work.

The age of citizen science, real citizen science, not a euphemism for amateur hour but genuine collaboration between motivated individuals and institutional experts enabled by AI, has arrived. What that age will look like depends on whether the rest of us are willing to learn enough to participate.